Angle success with ovarian cancer
Shares in technology investment firm Angle rose on Tuesday after it said its Parsortix cell separation device had passed an important milestone.
Shares in technology investment firm Angle rose on Tuesday after it said its Parsortix cell separation device had passed an important milestone.
The firm said that the device could now capture ovarian cancer cells, creating the possibility of developing an effective, non-invasive screening technique to enable the early diagnosis and monitoring of ovarian cancer.
Angle said that ovarian cancer usually had a poor prognosis and the mortality rate was disproportionately high because it lacked any clear early detection or screening test.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
This meant that most cases were not diagnosed until they have reached advanced stages.
"The successful capture and identification of cultured ovarian cancer cells added to blood is significant as it suggests that the Parsortix separation technology may work with all solid tumour cancers," said Angle's Chief Executive, Andrew Newland.
Angle said it had previously demonstrated that Parsortix could capture cultured breast cancer, prostate cancer, lung cancer and colon cancer cells added to blood.
Shares in the firm rose almost 4% following the announcement.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
UK-US trade deal announced: US cuts tariffs on UK car imports to 10%
Keir Starmer and Donald Trump have announced a UK-US trade deal, but the US president has refused to lift baseline tariffs on most UK goods. What does it mean for the UK?
-
How to use mid-caps to diversify from the US
Medium sized companies are overlooked by investors but could offer an attractive ‘sweet spot’. We consider the case for mid-caps amid market volatility.